Read here what's moving us right now.

We are pleased to announce that MEDIACC has officially received the “advisory status within the meaning of the current funding guidelines for the promotion of business consultancies for SMEs” in the area of evidence generation for medical devices.

This enables us to support our customers as part of this important funding program. The program, which is co-financed by the Federal Ministry of Economics and Climate Protection and the European Social Fund Plus, aims to support small and medium-sized enterprises (SMEs) in overcoming entrepreneurial challenges.

‍

For SMEs, our consulting covers all issues, in particular for the design of clinical trials of innovative products, including medical devices. This applies both to the generation of evidence as part of a conformity assessment process (CE certification), to extension of indications, to medical apps in the therapeutic or diagnostic sector, including DiGA and DiPA.

‍

As a registered consultant with the Federal Office of Economics and Export Control (BAFA), we meet strict quality standards. We have an appropriate quality assurance tool and ensure that advice is carried out properly, in accordance with the guidelines.

The funding rate is either 50% and a maximum of 1,750 euros or 80% and a maximum of 2,800 euros of consulting costs. Companies can receive funding for two consultations per year.

Contact us to find out more about how we can help you submit your application and help you further develop your innovative product with this funding.

MEDIACC is at your side as a competent partner to overcome your business challenges together and strengthen your company for the future.

‍

‍

Dear study participants,

Three years ago, with your generous support, you helped to reforest a forest in a climate-resilient way together with young people who planted the small plants. The trees that we planted back then have thrived and are now a living testimony to your commitment to a sustainable future. Your donations have enabled us to leave a legacy that is stronger than time. At MEDIACC, we are deeply grateful for your support and contribution to a livable planet. This forest is proof that every single action counts and that we can make a big difference together. Let us use this moment as an inspiration to continue to stand up for each other and for our planet.

Thanks again for your support. Your contribution will have an impact and bear fruit for a long time to come.

Kind regards

Your MEDIACC team

‍

‍

A breath of fresh air for the 2024 team relay

‍

In 2024, MEDIACC once again took part in the SCC 5x5 team relay. Great support came in particular from our hard-working, sometimes still dewy students, who supported us not only with our research work, but also on the racecourse across the zoo and on the picnic blanket. Both teams made it through the finish line sweaty but in good spirits. Just like their team teams, MEDIACC also does their studies: at high speed — with great effort — with full team spirit — and finally with success!

MEDIACC teaches leadership and self-management

‍

Developing and implementing strategies for self-management is part of MEDIACC's corporate culture. Every employee should be able to develop according to their strengths. For this purpose, an internal leadership seminar takes place every two weeks, in which potential managers are guided to recognize and promote their own qualities, to question beliefs and to break through negative circles of influence. Established methods are used as well as personal preferences. In this way, MEDIACC operates a particularly effective and future-proof tool for personnel development, which we are proud of.

Welcome, Works Council!

‍

Since spring, MEDIACC has been big enough for a works council. A newly appointed electoral board organized and carried out the election. Another big step has been taken for the development of our unique company! We are looking forward to seeing where the journey will take us.

🎉 Great news from MEDIACC for clinical trials! 🎉

‍

We are pleased to announce that our information security management system (ISMS) has once again been successfully recertified. This is a significant milestone that underscores the strength of our commitment to the highest security standards and data protection in conducting fully digital clinical trials.

Our renewed ISMS recertification guarantees that we protect the integrity and confidentiality of all data we manage at the highest level. Sensitive information from our patients is in safe hands on digital platforms. In this way, we ensure the efficiency and reliability of our digital study processes and a working environment that is based on trust and security. We continuously invest in technology and training to ensure that our team is at the forefront of secure data handling and protection procedures in this highly regulated area.

We are proud of our team and partners who work tirelessly to ensure that our systems and processes meet stringent safety requirements. This success once again reaffirms our commitment to excellence in all aspects of our work in a future-oriented, safe and dynamic environment.

MEDIACC: Celebrating Our Nomination as a Top 10 Clinical Trial Services Provider in Europe 2024

‍

At MEDIACC, we are thrilled and honoured to announce our recent nomination as one of the “Top 10 Clinical Trial Services Providers in Europe 2024.” This prestigious recognition demonstrates our continuous commitment to innovation, digital advancement, international collaboration, and scientific excellence.

First and foremost, we are immensely proud of our innovative leadership team, whose visionary guidance has propelled us to the forefront of the clinical research industry. Through their bold decision-making and forward-thinking approach, we have been able to redefine traditional trial practices and explore groundbreaking methodologies that drive medical innovation forward.

Our dedication to digital advancement has been a cornerstone of our success. We have invested significant resources in developing cutting-edge digital processes and structures specifically tailored for decentralised clinical trials of medical devices. By leveraging digital technologies, we have revolutionised trial procedures, enhanced patient accessibility, and accelerated the pace of medical progress.

Furthermore, our commitment to international collaboration has been instrumental in shaping our success. Through strategic partnerships with leading institutions and organizations worldwide, we have built a global network of expertise that enriches our research capabilities and fosters cross-cultural exchange.

Above all, our unwavering dedication to scientific rigor and quality has set us apart. From study design to data analysis, we uphold the highest standards of integrity and rigorously adhere to regulatory guidelines. Our team of skilled researchers and scientists ensures that every aspect of our work meets the most stringent criteria for validity and reliability, resulting in findings of unparalleled quality and credibility.

In Conclusion, Our Nomination Underscores Our Dedication to Excellence and Innovation in Clinical Research, Driving Us to Continuously Push Boundaries, Improve Patient Outcomes, and Shape the Future of Healthcare.

MEDIACC goes DMEA 2024

‍

For two days, we were represented at one of the most innovative trade fairs with MEDIACC and took advantage of the unique opportunity for personal exchange with a wide variety of national and international companies.

It is our aim to constantly and constantly improve our digital, decentralized clinical studies and to keep pace with innovations. The visit to DMEA provided the perfect platform for this: We had groundbreaking and intensive discussions with suppliers, manufacturers of market-oriented products, potential partners and customers as well as “old hands” and returned to the office full of exciting visions.

Successful accreditation of our AFORCE-1 study by the German Cancer Society's Colorectal Cancer Study Board

‍

We are pleased for our customer about the positive evaluation of the AFORCE-1 study by the German Cancer Society's Colorectal Cancer Study Board! Since 05.04.2024, the study on early cancer detection using a new blood test has been listed in the StudyBox under registration number ST-U178. The StudyBox is an internet-based platform that is currently being implemented as a pilot for colorectal cancer centers. Our study thus meets the criteria for recognition of the study within the certification system and is thus becoming more attractive for our test centers in the Berlin area.

Excellent clinical studies as an answer to the dilemma of statutory health insurance companies — not only in the reimbursement of DiGA

‍

In its latest and third DiGA report, the National Association of Statutory Health Insurance Funds for the Supply of Digital Health Applications (DiGA) summarizes. The board member at the National Association of Statutory Health Insurance Funds, Stefanie Stoff-Ahnis, demands equal treatment with other benefits reimbursed by statutory health insurance funds. DiGA is only granted the “potential” of medical benefit if there are “low entry requirements for DiGA when proving its benefits” and insufficient “economic efficiency.”

These statements are an affront to companies, which are undergoing a very complex process seriously and with great effort for innovative therapies. Equally against those responsible at the Federal Office for Drugs and Medical Devices (BfArM), who interpret the legal framework in such a way that even the provisional inclusion of a DiGA in the so-called DIGA directory requires higher standards of study quality and scientific evidence than the medical devices currently reimbursed, e.g. in the list of aids of the National Association of Statutory Health Insurance Funds, or when known useless therapies have ever been the case.

This undifferentiated and ill-considered presentation picked up by the press not only harms manufacturers but also all patients by preventing real innovation. Instead, the same scientific evidence requirements apply to all treatment options and fair payments for all services and to all care providers in this country should be considered and implemented based on facts.